

Drug and Therapeutics Committee – Minutes

Date / Time	February 10 th 2022 8.15-9.30
Venue	WebEx
Chair	Prof A Morice, Chair, Professor of Respiratory Medicine
Notes / Action Points	Luke Storr – Senior Pharmacy Technician, Formulary HUTH
Quorate: Yes / No	Yes

Attendance	Prof M Lind, Vice Chair, Professor of Oncology, HUTH Mr K McCorry, Medicines Optimisation Pharmacist, NECS Miss J Morgan, Professional Secretary, Principal Pharmacist – Formulary HUTH Dr O Ogunbambi, Consultant Rheumatologist, HUTH Ms J Goode, Chief Pharmacist, HUTH Mr P O'Brien, Deputy Chief Pharmacist, HUTH Mr R Kapur, Consultant Vascular Surgeon, HUTH Dr S Raise, GP Prescribing Lead, ER CCG Dr B Ali, GP Prescribing Lead, Hull CCG Dr A Samson, Consultant Infectious Diseases, HUTH
-------------------	---

Apologies	Dr H Klonin, Consultant Paediatrician, HUTH Prof T Sathyapalan, Consultant Endocrinologist, HUTH
------------------	---

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
2021.12.01	Apologies	As Above.					
2021.12.02	Declarations of Interest						
2021.12.03	Minutes of the previous meeting	Accepted as an accurate record	no action required				02/22
2021.12.04	Action Tracker	<p>Dissemination of Information Across All Healthcare Groups /Providers Extended for 6 months.</p> <p>Clinical Guidelines – Biologics and Small molecules in Inflammatory JM to request update of ustekinumab report prior to January meeting</p> <p>Hydroxychloroquine in RA – Guidelines in line with Royal college. Discussion on how to proceed, agreed to discuss with business managers of ophthalmology and rheumatology.</p> <p>Aria forms – Zoledronic acid JM checked with Dr Aye and no trust guidance. To author one from pharmacy in conjunction with DME pharmacy team.</p> <p>NICE TA735 (Tofacitinib in JIA) JM e-mailed NHSE awaiting response. Trust contracting confirmed HUTH not NHSE funded. Leeds attend our local MDT, so Leeds would have to do blueteq. But HUTH can prescribe</p> <p>New Product Requests AM to write to applicants</p> <p>New Product Requests JM to update formulary</p> <p>NG207 Inducing Labour JM to discuss misoprostol 25 microg product with Family and Womens pharmacist</p>	<p>To continue escalating and review in 6 months</p> <p>To request updated report for next meeting</p> <p>Ongoing</p> <p>Ongoing</p> <p>Action complete</p> <p>Action complete</p> <p>Action complete</p> <p>Ongoing</p>	<p>Add to May agenda</p> <p>Ongoing</p> <p>JM to contact relevant business managers</p> <p>To write guideline</p> <p>No further action</p> <p>No further action</p> <p>No further action</p> <p>To update next time</p>	<p>JM</p> <p>JM</p> <p>JM</p> <p>JM</p> <p>JM</p> <p>AM</p> <p>JM</p> <p>JM</p>	<p>5/22</p> <p>1/22</p> <p>03/22</p> <p>5/22</p> <p>12/21</p> <p></p> <p></p> <p>1/22</p>	<p></p> <p></p> <p></p> <p>2/22</p> <p>2/22</p> <p>2/22</p>

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
		<p>JM confirmed not on unlicensed medicine list and to contact obstetrics lead.</p> <p>TA742 Selpercatinib JM to update formulary and inform Dr Upadhyay</p> <p>TA743 Givosiran JM to confirm NHSE commissioning and update back of formulary</p> <p>NG126 Ectopic Pregnancy JM to check progesterone products to see if they fulfil guidance recommendations</p> <p>Clinical guidelines – Sarilumab JM to arrange upload onto Pattie</p> <p>Clinical guidelines Ronapreve® JM to arrange upload onto Pattie</p>	<p>Action complete</p> <p>Action complete</p> <p>Ongoing</p> <p>Action complete</p> <p>Action complete</p>	<p>No further action</p> <p>No further action</p> <p>To update next time</p> <p>No further action</p> <p>No further action</p>	<p>JM</p> <p>JM</p> <p>JM</p> <p>JM</p> <p>JM</p>	<p></p> <p></p> <p>1/22</p> <p></p> <p></p>	<p>2/22</p> <p>2/22</p> <p></p> <p>2/22</p> <p>2/22</p>
2021.12.05	New Product Requests	<p>New Product Requests</p> <ul style="list-style-type: none"> • Cenomabate (TA753) – Dr Taraferder JM summarised evidence. This is a new drug for epilepsy which is expected to be used as adjunctive therapy after failure of standard treatments. Product has a NICE TAG. To be discussed at next HERPC meeting • Ponesimod – Dr Harley JM summarised evidence. This is a new product for multiple sclerosis. When product request received product had a positive NICE FAD and now has a NICE TA767 • Clonidine patch (unlicensed medicine) – Dr Jose JM summarised limited evidence. Overall concern that the evidence for the product was poor but product has been in use in the US since 1980's form FDA licensed indication of 	<p>Approved</p> <p>Approved</p> <p>Approved with feedback in 6 months</p>	<p>AM to write to applicants LS to update formulary</p>	<p>AM/L S</p>	<p>3/22</p>	

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
		<p>hypertension. Both Leeds and Sheffield paediatric hospitals use the product and advice would be sort from specialist centre before starting. Evidence presented was poor but use in other places supports the effectiveness of product.</p> <p>Aria</p> <ul style="list-style-type: none"> Daratumumab plus bortezomib, thalidomide and dexamethasone. 	Approved				
2021.12.06	NICE guidance – November	<p>Nice Guidance December 2021</p> <ul style="list-style-type: none"> CG150 Headaches in over 12s: diagnosis and management TA755 Risdiplam for treating spinal muscular atrophy TA756 Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis – new product NG191 COVID-19 rapid guideline: managing COVID-19 NG12 Suspected cancer: recognition and referral NG131 Prostate cancer: diagnosis and management NG151 Colorectal cancer TA752 Belimumab for treating active autoantibody-positive systemic lupus erythematosus TA753 Cenobamate for treating focal onset seizures in epilepsy TA754 Mogamulizumab for previously treated mycosis fungoides and Sézary syndrome NG210 Pelvic floor dysfunction: prevention and non-surgical management TA750 Olaparib for maintenance treatment of BRCA mutation-positive metastatic pancreatic cancer after platinum-based chemotherapy (terminated appraisal) 	<p>Noted</p> <p>Not HUTH</p> <p>Requires aria form</p> <p>Noted</p> <p>Noted</p> <p>Noted</p> <p>Noted</p> <p>Requires NPR</p> <p>Discussed on agenda</p> <p>New product-require aria form</p> <p>Noted</p> <p>Terminated appraisal</p>	<p>No further actions</p> <p>To add to back of formulary</p> <p>Check for Aria form and updated back of formulary</p> <p>No further actions</p> <p>No further actions</p> <p>No further actions</p> <p>No further actions</p> <p>To add to back of formulary</p> <p>As per NPR</p> <p>To add to back of formulary</p> <p>No further actions</p> <p>No further actions</p>	<p>LS</p> <p>JM/LS</p> <p>LS</p> <p>LS</p>	<p>3/22</p> <p>3/22</p> <p>3/22</p> <p>3/22</p>	<p>2/22</p> <p>2/22</p> <p>2/22</p> <p>2/22</p> <p>2/22</p> <p>2/22</p>

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
		<ul style="list-style-type: none"> TA751 Dupilumab for treating severe asthma with type 2 inflammation TA748 Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disorders <p>JM to confirm with neurologists that would refer to specialist centre</p> <ul style="list-style-type: none"> TA749 Liraglutide for managing obesity in people aged 12 to 17 years (terminated appraisal) <p>January 2022</p> <ul style="list-style-type: none"> TA599 Sodium zirconium cyclosilicate for treating hyperkalaemia TA761 Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection NG211 Rehabilitation after traumatic injury TA760 Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer – already seen Aria form TA759 Fostamatinib for treating refractory chronic immune thrombocytopenia <p>JM to confirm with Haematology</p> <ul style="list-style-type: none"> TA757 Cabotegravir with rilpivirine for treating HIV-1 <p>New product which would require NPR – infectious disease team aware</p> <ul style="list-style-type: none"> TA758 Solriamfetol for treating excessive daytime sleepiness caused by narcolepsy <p>JM to confirm with Dr Ming if would be prescribed locally or referred to specialist.</p> <ul style="list-style-type: none"> NG81 Glaucoma: diagnosis and management NG191 COVID-19 rapid guideline: managing COVID-19 	<p>On formulary</p> <p>On unlicensed list</p> <p>Terminated appraisal</p> <p>Noted</p> <p>Aria form required</p> <p>Noted</p> <p>Noted</p> <p>Request Aria form</p> <p>Requires application</p> <p>Check for local usage</p> <p>Noted</p> <p>Noted</p>	<p>Set up homecare</p> <p>To confirm local usage and update back of formulary</p> <p>No further action</p> <p>To discuss at HERPC, to add to HERPC agenda</p> <p>Check for Aria forms</p> <p>No further actions</p> <p>No further actions</p> <p>Check for Aria form</p> <p>Update back of formulary and check for application</p> <p>Contact Dr Ming</p> <p>No further action</p> <p>No further action</p>	<p>LS</p> <p>JM/L S</p> <p>JM/L S</p> <p>JM</p> <p>JM</p> <p>JM/L S</p> <p>JM</p> <p>JM/L S</p> <p>JM</p>	<p>3/22</p> <p>3/22</p> <p>3/22</p> <p>3/22</p> <p>3/22</p> <p>3/22</p> <p>3/22</p> <p>3/22</p> <p>3/22</p>	<p>2/22</p> <p>2/22</p> <p>2/22</p> <p>2/22</p>
2021.12.07	MHRA Drug safety update – December 2021 and January 2022	Contents noted	Complete	No action required			02/22

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
2021.12.08	Minutes of the Safe Medication Practice Committee	Nil this month	Complete	No action required			02/22
2021.12.09	Minutes from the Hull and East Riding Prescribing Committee November 2021	Contents noted	Complete	No action required			02/22
2021.12.10	Regional Medicines Optimisation Committee	Nil this month					
2021.12.11	Clinical guidelines	Nil this month					
2021.12.12	Correspondence received	<ul style="list-style-type: none"> Commissioning recommendations for national procurement for direct acting oral anticoagulants (DOACs) January 2022 A national procurement has been finalised for DOACs that offers a potential financial benefit for using edoxaban for anticoagulation for AF. It was felt that HUTH could start patients on edoxaban for AF however could not change patients without clinical indication. This was due to potential risk at transfer of care. Covid-19 guidance – NHSE recently published multiple updates to COVID -19 treatment guidance and we have accepted latest antiviral and nMAB guideline to use Paxlovid®, in patients with immunosuppression to prevent hospital admission via the CMDU. 	<p>AM to write to thrombosis committee</p> <p>To update formulary</p>	<p>AM to write to thrombosis committee chair</p> <p>Update formulary</p>	<p>AM</p> <p>LS</p>	<p>3/22</p> <p>3/22</p>	
2021.12.13	Chairs Approvals	<ul style="list-style-type: none"> Everolimus – malignant thymoma with multiple myasthenic crisis – Prof Lind Tocilizumab – Covid-19 infection in immunocompromised patient – Dr Edey 	Complete	No action required			

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
		<ul style="list-style-type: none"> Cefoxitin – Paediatric CF patient with M abscessus infection – Dr Khan Belantamab mafodotin – myeloma – Dr Durairaj Interferon alfa – craniopharyngioma – Mr Kounin 					
2021.12.14	Issues to escalate to PE&CE	Nil to escalate	Complete	No action required			
2021.12.15	Any Other Business	Nil					
2021.12.16	Date and Time of Next Meeting	10 th March 2022 8:15 am					